Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - Arcturus Therapeutics (NASDAQ:ARCT) stock gained momentum after Cantor Fitzgerald maintained its Overweight rating on the company. According to InvestingPro data, six analysts have recently revised their earnings estimates upward, with a strong consensus recommendation of 1.27 (Strong Buy) and a notably bullish high price target of $140.
The research firm’s decision follows Arcturus’ disclosure of promising interim Phase 2 data from its U.S. and EU studies of ARCT-810 in ornithine transcarbamylase (OTC) deficiency, a rare urea cycle disorder.
ARCT-810 is an intravenously delivered mRNA therapy that encodes OTC, with a mechanism of action targeting the underlying cause of the disease. This approach could potentially impact most or all symptoms associated with the condition.
Despite limited doses and small sample sizes in the studies, Cantor Fitzgerald noted that biomarker data clearly suggests ARCT-810 is successfully delivered to the liver and expresses OTC at levels sufficient to enhance urea cycle activity, specifically ureagenesis.
The clinical progress of ARCT-810 represents a significant development for Arcturus Therapeutics in addressing ornithine transcarbamylase deficiency, a rare genetic disorder that can lead to dangerous ammonia buildup in the blood.
In other recent news, Arcturus Therapeutics Holdings Inc. reported positive interim results from its Phase 2 clinical trials of ARCT-810, an mRNA therapeutic for ornithine transcarbamylase (OTC) deficiency. The trials demonstrated significant reductions in glutamine levels, a key biomarker, and improvements in ureagenesis function, indicating potential therapeutic benefits. The treatment was generally well-tolerated, with no serious infusion-related reactions observed. Additionally, Scotiabank (TSX:BNS) initiated coverage on Arcturus with a Sector Outperform rating and a price target of $32, citing the company’s promising therapeutic pipeline. Cantor Fitzgerald maintained its Overweight rating on Arcturus shares following the company’s first-quarter financial results for 2025, which showed a net loss of $0.52 per basic share. Meanwhile, Canaccord Genuity adjusted its price target for Arcturus to $66, maintaining a Buy rating and highlighting the company’s focus on its cystic fibrosis and OTC programs. Arcturus continues to advance its clinical programs, with updates expected on its CF and OTC initiatives in 2025. These developments underscore the company’s strategic focus on its therapeutic pipeline and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.